Since uric acid level indicates an adverse metabolic condition, and HTN is considered a component of metabolic syndrome, the association between serum myonectin concentrations and the listed parameters determined in our study further supports the idea that serum myonectin concentrations (in particular, its increase in serum) may act as a marker of metabolic disorders and the body’s attempts to cope with them. This evidence concerns the gene ERFE and Other metabolic disease.